This trial is testing a new cancer drug, RP3, to see if it is safe and effective when used alone or in combination with another cancer drug.
6 Primary · 12 Secondary · Reporting Duration: Up to 3 years since first patient in
Experimental Treatment
123 Total Participants · 3 Treatment Groups
Primary Treatment: RP3 · No Placebo Group · Phase 1
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 100.0% |
18 - 65 | 100.0% |
MD Anderson Cancer Center | 100.0% |
Did not meet criteria | 100.0% |